• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
By KEVIN CURRAN Jul 29, 2019 | 08:47 AM EDT
Stocks quotes in this article: PFE, MYL, ARRY, AZN

Mylan (MYL)  shares shot higher on "Merger Monday" on word of a deal in which Pfizer Inc.  (PFE)  will combine its off-patent drug business with Mylan to form a new company.

"MYL shares could potentially benefit dramatically," Morgan Stanley analyst David Risinger had said in anticipation of such a deal. "Since MYL trades at an EV/2020e EBITDA multiple of only 6.5x, we believe shares could benefit from stronger earnings prospects."

In line with Risinger's assumption, Mylan shares were up about 15% before Monday's opening bell thanks to the planned combination and better-than-expected earnings at Mylan.

Mylan CEO and President Heather Bresch had been quiet on the company's prospects during a strategic review of options in May. The new deal brings that review, as well as Bresch's tenure, to a close.

Bresch had served as CEO of the company since 2012 and was popular fodder for healthcare-focused politicians.

If Mylan thinks health care should be a right, it might want to reconsider some of its practices like quadrupling the price of EpiPen while giving its CEO a 671% raise. https://t.co/EHRlemt64k

— Bernie Sanders (@SenSanders) May 2, 2018

The new company, which is yet to be named, will be led by Mylan Chairman Robert Coury, who will serve as executive chairman of the new company, and Michael Goettler, currently Group President of Pfizer's Upjohn unit, who will serve as CEO.

"Over the past year and a half, I have spent a lot of time speaking with and listening attentively to our shareholders. Today's announcement builds upon many of those meaningful conversations and represents a transformative move for Mylan," Coury said. "The new company, which combines the unique assets of Mylan with the iconic brands of Pfizer's Upjohn business, will not only accelerate our mission to serve the world's changing health needs, but also further unlock the true value of our platform while delivering attractive returns to shareholders for many years to come."

Minding the Merger Details

Per an announcement early Monday morning, Mylan will combine with Upjohn, Pfizer's off-patent branded and generic medicines business, in an all-stock transaction, with each Mylan share to be converted into one share of the new company.

Under terms of the deal, Pfizer shareholders will own 57% of the combined new company and Mylan shareholders will own 43%, greater than initially anticipated.

The deal will combine household names such as Pfizer's Lipitor, Celebrex, Zoloft and Viagra with a slate of drugs that includes Mylan's EpiPen while expanding the Mylan business beyond its heavy weighting toward U.S. generics.

"The transaction will allow the new company to meaningfully expand the geographic reach of Mylan's existing broad product portfolio and future pipeline -- including significant investments that have been made across complex generics and biosimilars -- into new growth markets where Upjohn has existing sales infrastructure and local market expertise," a Mylan statement reads.

Pfizer's expertise in China was specifically called out as a key driver for the newly combined company.

The new company is expected to have pro forma 2020 revenue of $19 billion to $20 billion, according to a company statement, with pro forma 2020 adjusted EBITDA expected to range from $7.5 billion to $8.0 billion, including phased synergies of about $1 billion annually to be realized by 2023.

"Merger creates a sizable NewCo focused on providing low cost drugs that is much more geographically diversified than Mylan's current business (we est. ~70% outside US sales mix of NewCo), thereby reducing exposure to US generics," Leerink Partners analyst Ami Fadia said. "[The deal] should position the NewCo to explore both internal and external growth opportunities in the future."

Fadia added that fresh management to examine the offerings at Mylan could provide more positive benefits in the long term, leading him to an "Outperform" rating on the shares.

Earnings Adds Accelerant

While not top of investors' minds, Mylan also reported better-than-expected second-quarter earnings on Monday morning.

The company reported non-GAAP earnings per share of $1.03 and revenue of $2.85 billion, both marking year-over-year gains and coming in above the Wall Street consensus.

"Mylan's second-quarter performance was strong as we delivered or exceeded on expectations across all financial metrics," departing CEO Heather Bresch said. "In addition, based upon our strong execution against our plan, we remain on track to deliver on our 2019 guidance."

Pfizer Falling

The footing for Pfizer shares has been decidedly less firm as its merger-and-acquisition (M&A) strategy picks up steam.

Pfizer shares were down nearly 3% in pre-market trading as details of the deal with Mylan emerged.

Earlier this year, Pfizer agreed to acquire Array Biopharma (ARRY) in an all-cash deal that values the cancer drug specialist at around $11.4 billion as Pfizer moves toward innovative medicines under new CEO Albert Bourla, who previously led Pfizer's Innovative Health Business, amid plans to reorganize its business into three separate units.

Yet another M&A splash adds complexity to Pfizer's overall business.

"The success of Pfizer's acquisitions (Hospira, Anacor, Medivation and AstraZeneca's (AZN) small molecule anti-infectives business) will depend, in large part, on the company's ability to realize anticipated benefits from combining these businesses with existing Pfizer segments," Cantor Fitzgerald analyst Louise Chen wrote. "For example, Pfizer may fail to achieve anticipated cost savings from the acquisition of Hospira, or such cost savings within the expected time frame; or the accretive impact anticipated from the acquisitions of Hospira, Anacor and Medivation may not be realized or may be delayed."

Nonetheless, Chen remained positive on Pfizer's overall prospects.

"We think this is a smart, strategic move by PFE and reflects well on new, CEO, Albert Bourla, who investors think has big shoes to fill with the retirement of former CEO Ian Read," she said. "PFE has talked about mid-single-digit operational revenue growth in the period post-2020 through 2025. If this deal goes through, we think the growth rate could be even higher, and this should drive multiple expansion."

A conference call to run through full results for Mylan's quarter and the implications for each company is expected to kick off at 8:30 a.m. here.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Mergers and Acquisitions | Regulation | Restructuring | Drug Approvals | Earnings | Investing | Stocks | Pharmaceuticals | China | Real Money | Stock of the Day

More from Stocks

Alibaba Shares Skyrocket in Hong Kong on Restructuring Plan

Alex Frew McMillan
Mar 29, 2023 8:00 AM EDT

The company will split into six separate entities which will be run under separate management and free to list independently.

I Wouldn't Plow Ahead With Buying Deere Despite an Analyst's Thumbs Up

Bruce Kamich
Mar 29, 2023 7:50 AM EDT

The technical picture of the farm equipment giant simply isn't encouraging.

Bank Regulations, Treasuries, Dwindling Trading Volumes, AMC, Amazon, Lockheed

Stephen Guilfoyle
Mar 29, 2023 7:26 AM EDT

These banking system steps would place increased drag on the velocity of money, which in turn will suppress economic growth.

The Bulls Are Trying Again, But Economic Uncertainty Will Keep Things Choppy

James "Rev Shark" DePorre
Mar 29, 2023 6:48 AM EDT

It's very messy action, and the primary reason for it is that there is a high level of uncertainty about where interest rates are heading.

What Goes Up in the Market, Doesn't Always Go Down in a Straight Line

Helene Meisler
Mar 29, 2023 6:00 AM EDT

Let's examine how once-hot bull market stocks can fall in a bear market, and why it's no time for complacency.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:00 PM EDT CHRIS VERSACE

    AAP Podcast: This Solar Company Is a Head-Turner

    Listen to my interview with Brian Roth, CEO of sol...
  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login